NICE TAs
- 15/05/2019
- TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
-
-
-
NICE guidance for lenvatinib (Lenvima) and sorafenib (Nexavar) for progressive, locally advanced or metastatic differentiated thyroid cancer in adults who have had radioactive iodine.
- 26/02/2020
- TA550: Vandetanib for treating medullary thyroid cancer
-
-
-
Evidence-based recommendations on vandetanib (Caprelsa) for treating medullary thyroid cancer in adults.
- 15/05/2019
- TA553: Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence.
-
-
-
Evidence-based recommendations on pembrolizumab (Keytruda) for adjuvant treatment of stage III melanoma with lymph node involvement in adults.
- 27/02/2020
- TA586: Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib
-
-
-
Evidence-based recommendations on lenalidomide (Revlimid) plus dexamethasone for multiple myeloma after 1 treatment with bortezomib in adults.
- 02/09/2019
- TA587: Lenalidomide plus dexamethasone for previously untreated multiple myeloma
-
-
-
Evidence-based recommendations on lenalidomide (Revlimid) plus dexamethasone for previously untreated multiple myeloma in adults.
- 27/02/2020
- TA409: Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion
-
-
-
Evidence-based recommendations on aflibercept (Eylea) for treating visual impairment caused by macular oedema after branch retinal vein occlusion.